6-Bromoindirubin-3'-oxime Promotes Human Mesenchymal Stem Cell Proliferation, Stem Cell Phenotype, and Population Homogeneity

Applications:  Currently, large orthopedic fractures (>3mm) presents a challenge clinically as proliferation of cells that differentiate into osteochondral cell types is required to heal the fracture. This technology provides a method, using a specific molecule, for inducing the proliferation of human mesenchymal stem cells (hMSC) in vitro. This increased proliferation has potential applications in regenerative medicine by providing a means for the robust expansion of in vivo transplanted patient-specific stem cells and providing homogeneous, multipotent cells for differentiation and tissue evolution.


Advantages:  Most current technologies that are used to maintain stemness and enhance MSC proliferation rely on growth factors, which are often variable and are expensive. This technology, instead, utilizes a small molecule drug that is not variable and is inexpensive. Additionally, to achieve proliferation and maintain stemness this technology only requires one short (24h) dosage, whereas current strategies require long-term dosage. 

URV Reference Number: 2-11149-11029
Patent Information:
For Information, Contact:
Matan Rapoport
Licensing Associate
University of Rochester
Danielle Benoit
Michael Hoffman